Loading the section
iPROMOMED (PRMD): the company is profitable, net margin 18.7%; profit is not backed by cash, cash flow to profit −0.61×. Dividends are irregular, yield 2.0%. The debt load is moderate, net debt / EBITDA 1.44×. Data as of 19 June 2026.
Answers to 4 of 4 questions
What share of revenue the company keeps as profit
Data as of 5 October 2026
Does the company pay dividends regularly and can it afford the payout
Data as of 19 June 2026
How large the company's debt is relative to its earnings
Data as of 5 October 2026
P/E · IFRS · Price as of 1 April 2026
Based on the 2025 annual report, P/E is 12.25×. The valuation history is still too short to compare the share with its own past: observations: 1.
By report year
P/E
The share has not had a similar valuation in its history yet.
A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.
Dividends are irregular, yield 2.0%. The last payout was RUB 8.00 per share.
The debt load is moderate, net debt / EBITDA 1.44×. Net debt is RUB 21.69 bn.
The company is profitable, net margin 18.7%. Net income is RUB 7.04 bn.
Based on the 2025 annual report, P/E is 12.25×. The valuation history is still too short to compare the share with its own past: observations: 1.
What date the figures on this page are as of
The analysis is built on the issuer's published financial statements and disclosures. It is information, not investment advice.
Is the company's profit backed by real cash
Data as of 5 October 2026